Clinical trial · Interventional
Resistance and Aerobic Exercise for Subclinical Anthracycline Cardiomyopathy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This application proposes a prospective, single arm feasibility clinical trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function. Baseline and post intervention imaging, laboratory, and neuropsychological evaluations will be used to determine the effects of the intervention on body composition, serum lipid profile, exercise tolerance, and neurocognitive functioning. Participants will be called weekly to monitor compliance with the intervention. Incentives will be given at intervals during the trial to optimize compliance with the intervention.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiomyopathy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 12 Week Exercise Intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Exercise Group
- description
- Survivors of childhood cancer treated with anthracyclines and known to have cardiomyopathy will participate in a 12 week exercise intervention.
- interventionNames
- Other: 12 Week Exercise Intervention
Primary outcomes (1)
- measure
- The primary aim of this proposal is to evaluate the feasibility of a 12-week exercise intervention among survivors of childhood cancer treated with anthracyclines and known to have cardiomyopathy.
- timeFrame
- 12 Weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Treated at St. Jude Children's Research Hospital (SJCRH) * Ages 0 - 17 years at time of treatment * Treated for any type of cancer * ≥ 10 years from date of diagnosis * ≥ 2 years after completion of active cancer therapy * ≥ 18 years of age * Treated with doxorubicin and/or daunorubicin (any cumulative dose) * Ejection fraction of \< 55% without medications * Does not currently meet the Centers for Disease Control (CDC) recommendations for exercise for adults Exclusion Criteria: * Ejection fraction ≤ 40% * Pregnant females (Positive Urine pregnancy Test). * History of congenital heart disease * History of myocardial infarction * History of acute coronary syndrome * Individuals with pacemakers or implanted defibrillators * History of radiation therapy that included any part of the heart * ≥1-mm J-point depression (depression measured 80 msec after J-point) with ST segment flat or down-sloping in the majority of complexes in any ECG lead except AVR with exercise testing. * All patients will be classified using the recommendations of the American Heart Association. Patients found to be in Class A, C or Class D will not be eligible for study
References
Publications (0)
Data not yet available